Microbiologic epidemiology depending on time to occurrence of prosthetic joint infection: a prospective cohort study

Clin Microbiol Infect. 2019 Mar;25(3):353-358. doi: 10.1016/j.cmi.2018.04.035. Epub 2018 May 25.

Abstract

Objectives: The high microbiologic diversity encountered in prosthetic joint infection (PJI) makes the choice of empirical antimicrobial therapies challenging, especially in cases of implant retention or one-stage exchange. Despite the risk of dysbiosis and toxicity, the combination of vancomycin with a broad-spectrum β-lactam is currently recommended in all cases, even if Gram-negative bacilli (GNB) might be less represented in late PJI. In this context, this study aimed to describe the microbiologic epidemiology of PJI according to the chronology of infection.

Methods: This prospective cohort study (2011-2016) evaluated the microbiologic aetiology of 567 PJI according to time of occurrence from prosthesis implantation-early (<3 months), delayed (3-12 months) and late (>12 months)-as well as mechanism of acquisition.

Results: Initial microbiologic documentation (n = 511; 90.1%) disclosed 164 (28.9%) Staphylococcus aureus (including 26 (16.1%) methicillin-resistant S. aureus), 162 (28.6%) coagulase-negative staphylococci (including 81 (59.1%) methicillin-resistant coagulase-negative staphylococci), 80 (14.1%) Enterobacteriaceae, 74 (13.1%) streptococci and 60 (10.6%) Cutibacterium acnes. Considering nonhaematogenous late PJI (n = 182), Enterobacteriaceae (n = 7; 3.8%) were less represented than in the first year after implantation (n = 56; 17.2%; p <0.001), without difference regarding nonfermenting GNB (4.6% and 2.7%, respectively). The prevalence of anaerobes (n = 40; 21.9%; including 32 (80.0%) C. acnes) was higher in late PJI (p <0.001). Consequently, a broad-spectrum β-lactam might be useful in 12 patients (6.6%) with late PJI only compared to 66 patients (20.3%) with early/delayed PJI (p <0.001).

Conclusions: Considering the minority amount of GNB in late postoperative PJI, the empirical use of a broad-spectrum β-lactam should be reconsidered, especially when a two-stage exchange is planned.

Keywords: Antimicrobial therapy; Empiric; Epidemiology; Microbiology; Prosthetic joint infection.

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Arthritis, Infectious / drug therapy*
  • Arthritis, Infectious / microbiology*
  • Bacteria / growth & development
  • Bacterial Physiological Phenomena*
  • Female
  • Humans
  • Joint Prosthesis / adverse effects*
  • Male
  • Middle Aged
  • Prospective Studies
  • Prosthesis-Related Infections / drug therapy*
  • Prosthesis-Related Infections / microbiology*
  • Time Factors

Substances

  • Anti-Bacterial Agents